Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria
Irbesartan Versus Placebo in Combination With Standard Cardiovascular Protection ACE-I Therapy With Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk
Sponsor: Bristol-Myers Squibb
A PHASE4 clinical study on Albuminuria, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 9 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .